OraSure Sees Profitability In 2002 With OraQuick, UPlink Introductions
This article was originally published in The Gray Sheet
Executive SummaryOraSure Technologies expects FDA approvals of its UPlink drugs-of-abuse test and OraQuick rapid HIV assay to help the firm reach profitability this year and grow revenues 30% over 2001
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.